Amid the flurry of activity at the American College of Cardiology 2022 Scientific Session, Anum Saeed, MD, reports on the positive results of the APOLLO trial, which support the efficacy of the short interfering RNA agent SLN360 in reducing lipoprotein (a) levels. This is a watershed moment in the treatment of this lipid disorder, which currently has no direct, approved therapeutic agent.
Dr Saeed cautions that the phase 2 and 3 trials must still occur before SLN360 is ready for "prime time"; however, early results offer promise to those afflicted by this disorder.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ACC 2022: A Step Towards Prime Time for a Breakthrough in Lipid Management - Medscape - Apr 07, 2022.